Prescribing and Managing Antipsychotics
Thomas Schwartz, MD. Professor and Interim Chair of Psychiatry and Behavioral Sciences, Upstate Medical University, Syracuse, NY. Dr. Schwartz has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Michael Weaver, MD
Professor and medical director at the Center for Neurobehavioral Research on Addiction at the University of Texas Medical School. Author of Addiction Treatment (Carlat Publishing, 2017).
Dr. Weaver has disclosed that he received payment from Indivior in the past 12 months. Dr. Carlat has reviewed this article and has found no evidence of bias in this educational activity.
Kevin P. Hill, MD
Director, Division of Addiction Psychiatry, Beth Israel Deaconess Medical Center, and assistant professor of psychiatry at Harvard Medical School.
Dr. Hill has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.webp?t=1729528747)



